Agenus' HerpV Therapeutic Genital Herpes Vaccine Meets Primary Endpoint in Randomized Phase 2 Trial
November 07, 2013 at 07:05 AM EST
Agenus (NASDAQ: AGEN ) today announced statistically significant top-line results from its Phase 2 randomized, double-blind, multi-center study for HerpV, a recombinant “off-the-shelf” therapeutic vaccine candidate for
